25 June 2026
Advocate General Szpunar Makes Questionable Proposal to Relax Language Requirements for Labelling of Parallel-Traded Medicinal Products
10 min read
On 11 June 2026, Advocate General Szpunar delivered his non-binding Opinion concerning the application of labelling and national language requirements under Directive 2001/83/EC “on medicinal products for human use” to parallel-imported medicinal products.
The Opinion is highly questionable and, if followed by the Court of Justice of the European Union, would mark yet another step in the gradual erosion of public health protection in favour of the free movement of parallel-traded goods.
Attached is a note discussing the Opinion.
Attachments:
Key contacts
News & insights
1 min
read
read
News
VBB contributes article on Belgium FDI regime to GCR – Foreign Direct Investment Regulation Hub 2027
16 November 2026
2 min
read
read
News
Dutch Competition Authority Investigates Biogen for Possible Bundling of Multiple Sclerosis Treatment and Diagnostic
6 November 2026
1 min
read
read
News
VBB advises Mankind Pharma on two strategic investments in next-generation CAR-T therapies for cancer
28 October 2026
1 min
read
read
News
Fabrizio Di Gianni to speak at the Steel Networking Summit 2026
19 October 2026
3 min
read
read
News
Sanofi Avoids European Commission Fine Despite Making Derogatory Statements regarding Rival’s Flu Vaccine
15 October 2026
3 min
read
read
News
Belgian Competition Authority Begins to Address AI Antitrust Concerns
12 October 2026